ACADIA Pharmaceuticals Inc (NAS:ACAD)
$ 16.95 -0.42 (-2.42%) Market Cap: 2.89 Bil Enterprise Value: 2.37 Bil PE Ratio: 22.27 PB Ratio: 5.01 GF Score: 75/100

ACADIA Pharmaceuticals Inc at Guggenheim Securities Inflammation & Immunology Conference Transcript

Nov 07, 2023 / 09:30PM GMT
Release Date Price: $23.5 (-2.00%)
Eddie Hickman
Guggenheim Securities, LLC, Research Division - Research Analyst

All right. Welcome back, everyone, to the final session of Guggenheim's I&I Conference. My name is Eddie Hickman. I'm one of the biotech analysts here. And I'm joined today by some of the ACADIA management team, CFO, Mark Schneyer; and Doug Williamson, the Head of R&D. Welcome, gentlemen. Mark, do you maybe want to give -- spend 5 minutes giving us a quick overview of the company? And maybe you just recently reported earnings. So maybe just give us a summary of what you saw on some of the programs that are going ahead.

Mark C. Schneyer
ACADIA Pharmaceuticals Inc. - Executive VP & CFO

Yes, happy to do it. Thank you for having us. So at ACADIA, we're developing and commercializing novel medicines in CNS disorders. We're a commercial-stage organization as well as we have a pipeline behind it. The 2 commercial stage assets. So you alluded to DAYBUE, which is the first and only approved product to treat Rett syndrome, which is a neurodevelopmental disorder. It was approved

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot